About StemCyte
It is not just saving cord blood.
It is about Saving Lives.
StemCyte embraces the philosophy “Better Cell, Better Life” and is dedicated to advancing cell-therapy applications to address diseases that currently lack curative treatments—helping build a healthier future.
Founded in the United States in 1997 with a concurrent presence in Taiwan, StemCyte has built a public cord blood inventory of more than 36,000 publicly donated cord blood units (CBUs), making it one of the world’s largest, with broad HLA/ethnic diversity and rigorous quality standards. It is also among the few biotechnology companies that operate both public and private cord blood banks.
Over the past two decades, StemCyte has released more than 2,300 CBUs for transplantation to 350+ transplant centers worldwide. In November 2024, it became the world’s first private enterprise to receive U.S. FDA approval of its Biologics License Application (BLA) for a cord-blood–derived product. Looking ahead, StemCyte will continue to advance the development and application of cord blood–based cell therapies, providing safe, high-quality cellular resources to physicians and patients around the world.
R&D Team & Cell Therapy Solutions.
StemCyte has professional management and R&D teams spanning the United States and Taiwan, with core capabilities in new drug development, manufacturing, clinical trials, and international sales.
StemCyte collaborates with leading international medical centers—including City of Hope (USA), Taipei Medical University Hospital, and Tzu Chi Hospital—on multiple clinical trials, including those for long COVID, acute stroke, cerebral palsy, and cancer immunotherapy.
20 years of unremitting efforts
StemCyte upholds the highest standards and has achieved international certifications from AABB and FACT in both the US and Taiwan, providing high-quality and high-activity cell therapy products.
Since 2012, StemCyte US has collaborated with the California government and the UC Davis to implement the “Umbilical Cord Blood Collection Program (UCBCP)”, providing cord blood for transplantation and research to the California government, making it one of the few private companies trusted by the US government for such collaborations.